Apr 8, 2021 — 3 min read
A research team at the Karolinska Institutet in Sweden will assess the performance of AI startup Lunit’s breast cancer AI software as an independent mammography reader in screening
This groundbreaking prospective study marks the first of its kind, aiming to screen 55,000 women with mammography at Capio Sankt Gorans Hospital in Stockholm, Sweden
Lunit will participate in the new study conducted by the research team of Karolinska Institutet in Sweden. According to Lunit, this research is the first prospective study in Europe to validate the performance of AI in an actual clinical trial of screening mammography.
Dr. Fredrik Strand and his research team at Karolinska Institutet will assess the performance of Lunit INSIGHT MMG combined with radiologists in a true screening population, compared to the “double-reading” standard-of-care in Europe, in which two radiologists assess screening mammograms. Lunit INSIGHT MMG CE marked and currently commercially available in Europe.
“There have been multiple retrospective studies to validate AI performance, but there have not been any prospective studies to assess AI’s clinical utility in an actual clinical setting,” said Brandon Suh, CEO of Lunit. “Documentational processes such as licensing and regulatory approvals for an AI solution are mandatory, but assessing the actual effectiveness of its performance in clinical trials is of vital importance. We look forward to finding a meaningful result to bring deeper understanding of our AI solution.”
The target volume of the study includes 55,000 patients, in collaboration with Capio Sankt Görans Hospital of Sweden. It is one of the largest screening centers in Sweden with a high cancer detection rate. The expected timeline for the study is two years. Anders Byström, head of Radiology at the hospital, is intrigued: “We are truly looking forward to understanding whether AI can make our screening process even more efficient”
Fredrik Strand, principal investigator at the Department of Oncology-Pathology at Karolinska Institutet and a radiologist at Karolinska University Hospital explained “We were impressed by the results of Lunit INSIGHT MMG in our retrospective trials. It will be interesting to see how it plays out in a clinical setting.”
Last year, Dr. Strand’s research team conducted the first independent comparison of three commercialized AI to identify breast cancer. Among them, Lunit’s algorithm showed the best accuracy with around 15 percentage points higher sensitivity compared to the other two algorithms, and also surpassed the sensitivity of one of two radiologists. The study was published in JAMA Oncology.
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Uncertainty and Deep Learning
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
AI Can Offer Fast and Reliable Examination to Triage COVID-19 Patients-- A Multicenter Retrospective Study Reveals
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do medical studies say about AI for COVID-19 management?
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
AACR 2021 - Lunit Presents Abstracts Demonstrating the Potential of its AI Biomarker in Cancer Treatment
Case of the Month | Where Is Breast Cancer?
AI-based Analysis of Cancer Tissue Predicts Response to Immunotherapy--Findings to Be Presented at ASCO 2021